Andrea Foli
Research Subjects
Research Interests
Andrea Foli has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Palladini
University of Pavia and Foundation IRCCS Policlinico San Matteo, Pavia, Italy
10 shared publications - Giampaolo Merlini
Amyloid Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, and University of Pavia
9 shared publications - Paolo Milani
Department of Molecular Medicine, University of Pavia, Pavia, Italy
8 shared publications - Marco Basset
Department of Molecular Medicine, University of Pavia, Pavia, Italy
7 shared publications - Francesca Lavatelli
Department of Molecular Medicine, University of Pavia, and Research Area, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
4 shared publications Mario Nuvolone
Department of Molecular Medicine, University of Pavia, Pavia, Italy
4 shared publications
Latest Publications
- Open Access
- 29 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (9) , 2221-2225
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study
- 29 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (9) , 2221-2225
Open AccessDiffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study
- 3 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (18) , 1964-1971
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival
Patients with immunoglobulin light chain (AL) amyloidosis and stage IIIb cardiac involvement have a dismal outcome despite the introduction of novel treatments. However, a rapid hematologic response translates in better survival. We evaluated the impact of early cardiac response and its depth on outcome in 249 patients with newly diagnosed stage IIIb cardiac AL amyloidosis. Hematologic and cardiac responses were evaluated by intent to treat. After a median follow-up of 52 months, 219 (84%) patients died, and median survival was 4.2 months. The 30- and 90-day hematologic response rates were 22% (at least very good partial response [VGPR] in 9%) and 24% (at least VGPR in 15%), respectively. Early hematologic response resulted in better survival. At 90 days, 21 (8%) patients achieved a cardiac response (cardiac very good partial response [cardiac VGPR] in 12 cases and cardiac partial response [cardiac PR] in 9). At the 90-day landmark analysis, cardiac response resulted in longer survival (median, 54 months), also in those patients who have achieved at least VGPR (median, 62 vs 26 months, P = .011). Patients with cardiac VGPR had a longer survival than those with cardiac PR (median, 92 vs 24 months; P = .027), whereas patients without cardiac response had a poor survival (median, 6 months). A baseline difference of involved/uninvolved free light chains > 50 mg/L (odds ratio [OR], 0.21, P = .024) and a bone marrow plasma cell infiltrate > 10% (OR, 0.23, P = .040) were negative predictors of 90-day cardiac response. Early cardiac responses are rare but possible in stage IIIb AL amyloidosis and translate to longer survival.
- 3 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (18) , 1964-1971
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival
Patients with immunoglobulin light chain (AL) amyloidosis and stage IIIb cardiac involvement have a dismal outcome despite the introduction of novel treatments. However, a rapid hematologic response translates in better survival. We evaluated the impact of early cardiac response and its depth on outcome in 249 patients with newly diagnosed stage IIIb cardiac AL amyloidosis. Hematologic and cardiac responses were evaluated by intent to treat. After a median follow-up of 52 months, 219 (84%) patients died, and median survival was 4.2 months. The 30- and 90-day hematologic response rates were 22% (at least very good partial response [VGPR] in 9%) and 24% (at least VGPR in 15%), respectively. Early hematologic response resulted in better survival. At 90 days, 21 (8%) patients achieved a cardiac response (cardiac very good partial response [cardiac VGPR] in 12 cases and cardiac partial response [cardiac PR] in 9). At the 90-day landmark analysis, cardiac response resulted in longer survival (median, 54 months), also in those patients who have achieved at least VGPR (median, 62 vs 26 months, P = .011). Patients with cardiac VGPR had a longer survival than those with cardiac PR (median, 92 vs 24 months; P = .027), whereas patients without cardiac response had a poor survival (median, 6 months). A baseline difference of involved/uninvolved free light chains > 50 mg/L (odds ratio [OR], 0.21, P = .024) and a bone marrow plasma cell infiltrate > 10% (OR, 0.23, P = .040) were negative predictors of 90-day cardiac response. Early cardiac responses are rare but possible in stage IIIb AL amyloidosis and translate to longer survival.
- 23 August 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (11) , E389-E392
Single‐molecule real‐time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies
- 23 August 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (11) , E389-E392
Single‐molecule real‐time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies
- Open Access
- 4 September 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (17) , 4175-4179
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis
Autologous stem cell transplant (ASCT) is highly effective in selected patients with light chain (AL) amyloidosis. Bortezomib, preceding or following ASCT, improves responses. Satisfactory responses, including at least a partial response, very good partial response (VGPR) with organ response, or complete response, can be observed after induction therapy alone. We report 139 patients treated upfront with cyclophosphamide/bortezomib/dexamethasone (CyBorD), followed by ASCT only if response was unsatisfactory. Only 1 treatment-related death was observed. After CyBorD, hematologic response (HR) rate was 68% (VGPR or better, 51%), with 45% satisfactory responses. Transplant was performed in 55 (40%) subjects and resulted in an 80% HR rate (65% ≥ VGPR). Five-year survival was 86% and 84% in patients treated with ASCT or CyBorD alone, respectively (P = .438). Also, 6- and 12- month landmark analyses did not show differences in survival. Duration of response was not different in the 2 groups (60 vs 49 months; P = .670). Twenty-one (15%) patients with an unsatisfactory response to CyBorD could not undergo ASCT because of ineligibility or refusal; instead, they received rescue chemotherapy, with HR in 38% of cases and 51% 5-year survival. This sequential response-driven approach, offering ASCT to patients who do not attain satisfactory response to upfront CyBorD, is very safe and effective in AL amyloidosis.
- 4 September 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (17) , 4175-4179
Open AccessSequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis
Autologous stem cell transplant (ASCT) is highly effective in selected patients with light chain (AL) amyloidosis. Bortezomib, preceding or following ASCT, improves responses. Satisfactory responses, including at least a partial response, very good partial response (VGPR) with organ response, or complete response, can be observed after induction therapy alone. We report 139 patients treated upfront with cyclophosphamide/bortezomib/dexamethasone (CyBorD), followed by ASCT only if response was unsatisfactory. Only 1 treatment-related death was observed. After CyBorD, hematologic response (HR) rate was 68% (VGPR or better, 51%), with 45% satisfactory responses. Transplant was performed in 55 (40%) subjects and resulted in an 80% HR rate (65% ≥ VGPR). Five-year survival was 86% and 84% in patients treated with ASCT or CyBorD alone, respectively (P = .438). Also, 6- and 12- month landmark analyses did not show differences in survival. Duration of response was not different in the 2 groups (60 vs 49 months; P = .670). Twenty-one (15%) patients with an unsatisfactory response to CyBorD could not undergo ASCT because of ineligibility or refusal; instead, they received rescue chemotherapy, with HR in 38% of cases and 51% 5-year survival. This sequential response-driven approach, offering ASCT to patients who do not attain satisfactory response to upfront CyBorD, is very safe and effective in AL amyloidosis.
- Open Access
- 6 April 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (7) , 1321-1324
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function
Key Points: Daratumumab is effective in treated light chain deposition disease. Daratumumab can prevent progression of renal failure in these patients.
- 6 April 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (7) , 1321-1324
Open AccessDaratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function
Key Points: Daratumumab is effective in treated light chain deposition disease. Daratumumab can prevent progression of renal failure in these patients.
- Open Access
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 1860
Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis
INTRODUCTION: Daratumumab has been recently introduced in the treatment of patients with multiple myeloma (MM). Two phase II trials of this drug in relapsed/refractory AL amyloidosis were recently completed, but final reports have not been published so far. One randomized phase III trial in treatment-naïve patients with this diseases has recently completed enrollment and the results are eagerly awaited. However, several retrospective series showed encouraging response rates with daratumumab alone or in combination with bortezomib or immune modulatory drugs in AL amyloidosis. After this drug was marketed for MM in Italy, it became routinely accessible also to patients with myeloma-associated AL amyloidosis (MM-AL). We evaluated the efficacy of daratumumab in a consecutive series of patients with MM-AL in three centers of the Italian Amyloidosis Study Group. METHODS: Consecutive patients with a diagnosis of MM-AL treated with daratumumab were included in the study. Patients received daratumumab 16 mg/Kg body weight e.v. once a week for the first two months and then every other week for the next four months and subsequently every 28 days. The standard DVd (daratumumab, bortezomib and dexamethasone) and DRd (daratumumab, lenalidomide and dexamethasone) regimens were also used in subsets of patients. Hematologic and organ responses were assessed according to the International Society of Amyloidosis (ISA) criteria. RESULTS: Seventy-two patients were included in the study (61 in Pavia, 10 in Padua and 1 in Turin), Table. Median age was 61 years (range: 37-79 years) and 45 (63%) patients were males. The heart and the kidney were involved in 49 patients each (68%). Median bone marrow plasma cell infiltrate was 18% (range: 11-50%). Median time from diagnosis to treatment initiation was 32 months (range: 3-185 months). Fifty (69%) patients were refractory to the line of therapy immediately preceding daratumumab. Median number of prior treatments was 2 (range: 1-9) and daratumumab was used as second line option in 20 (28%) cases. Forty-seven (65%) patients received daratumumab as single agent. The remaining patients received DVd 14 (19%) and DRd in 11 (15%) cases. After 8 infusions 59 (82%) patients achieved a hematologic response (HR): complete response (CR) in 12 (16%), very good partial response (VGPR) in 30 (42%) and partial response (PR) in 17 (24%). Cardiac response was observed in 9 of 37 evaluable patients (24%) and renal response in 21 of 38 patients (55%). Among patients in VGPR, 4 did not qualify for CR due to the persistence of an abnormal free light chain (FLC) ratio (FLCR) despite normalization of involved FLC (iFLC) due to lower than normal levels of uninvolved FLC, while serum and urine immunofixation were negative. After 16 infusions there was only a modest improvement of overall HR rate (60 patients, 83%), but quality of response improved: with CR in 22 patients (30%), VGPR in 21 (29%), and PR in 17 (24%). Of the 4 patients in iFLC-response after 8 infusions, 2 qualified for CR with normalization of FLCR after 16 infusions. In the other 2 patients FLCR did not normalize and we found persistence of the amyloid light chain at high-resolution immunofixation of serum and/or urine. No difference in HR was seen between patients treated with daratumumab single agent and those who received daratumumab combinations (after 16 infusions 81% vs. 88%, P=0.470). After 16 infusions, cardiac response was observed in 11 of 37 evaluable patients (29%) and renal response in 23 of 38 patients (60%). After a median follow-up of living patients after daratumumab initiation of 12 months, 5 subjects died due to disease progression and projected survival at 1 year was 95%. CONCLUSION: Daratumumab is effective in heavily pretreated patients with MM associated AL amyloidosis. Quality of response improved over time with 60% of patients achieving CR or VGPR after 16 infusions. Suppression of uninvolved FLC may result in delayed normalization of FLC ratio in some patients.
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 1860
Open AccessTreatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis
INTRODUCTION: Daratumumab has been recently introduced in the treatment of patients with multiple myeloma (MM). Two phase II trials of this drug in relapsed/refractory AL amyloidosis were recently completed, but final reports have not been published so far. One randomized phase III trial in treatment-naïve patients with this diseases has recently completed enrollment and the results are eagerly awaited. However, several retrospective series showed encouraging response rates with daratumumab alone or in combination with bortezomib or immune modulatory drugs in AL amyloidosis. After this drug was marketed for MM in Italy, it became routinely accessible also to patients with myeloma-associated AL amyloidosis (MM-AL). We evaluated the efficacy of daratumumab in a consecutive series of patients with MM-AL in three centers of the Italian Amyloidosis Study Group. METHODS: Consecutive patients with a diagnosis of MM-AL treated with daratumumab were included in the study. Patients received daratumumab 16 mg/Kg body weight e.v. once a week for the first two months and then every other week for the next four months and subsequently every 28 days. The standard DVd (daratumumab, bortezomib and dexamethasone) and DRd (daratumumab, lenalidomide and dexamethasone) regimens were also used in subsets of patients. Hematologic and organ responses were assessed according to the International Society of Amyloidosis (ISA) criteria. RESULTS: Seventy-two patients were included in the study (61 in Pavia, 10 in Padua and 1 in Turin), Table. Median age was 61 years (range: 37-79 years) and 45 (63%) patients were males. The heart and the kidney were involved in 49 patients each (68%). Median bone marrow plasma cell infiltrate was 18% (range: 11-50%). Median time from diagnosis to treatment initiation was 32 months (range: 3-185 months). Fifty (69%) patients were refractory to the line of therapy immediately preceding daratumumab. Median number of prior treatments was 2 (range: 1-9) and daratumumab was used as second line option in 20 (28%) cases. Forty-seven (65%) patients received daratumumab as single agent. The remaining patients received DVd 14 (19%) and DRd in 11 (15%) cases. After 8 infusions 59 (82%) patients achieved a hematologic response (HR): complete response (CR) in 12 (16%), very good partial response (VGPR) in 30 (42%) and partial response (PR) in 17 (24%). Cardiac response was observed in 9 of 37 evaluable patients (24%) and renal response in 21 of 38 patients (55%). Among patients in VGPR, 4 did not qualify for CR due to the persistence of an abnormal free light chain (FLC) ratio (FLCR) despite normalization of involved FLC (iFLC) due to lower than normal levels of uninvolved FLC, while serum and urine immunofixation were negative. After 16 infusions there was only a modest improvement of overall HR rate (60 patients, 83%), but quality of response improved: with CR in 22 patients (30%), VGPR in 21 (29%), and PR in 17 (24%). Of the 4 patients in iFLC-response after 8 infusions, 2 qualified for CR with normalization of FLCR after 16 infusions. In the other 2 patients FLCR did not normalize and we found persistence of the amyloid light chain at high-resolution immunofixation of serum and/or urine. No difference in HR was seen between patients treated with daratumumab single agent and those who received daratumumab combinations (after 16 infusions 81% vs. 88%, P=0.470). After 16 infusions, cardiac response was observed in 11 of 37 evaluable patients (29%) and renal response in 23 of 38 patients (60%). After a median follow-up of living patients after daratumumab initiation of 12 months, 5 subjects died due to disease progression and projected survival at 1 year was 95%. CONCLUSION: Daratumumab is effective in heavily pretreated patients with MM associated AL amyloidosis. Quality of response improved over time with 60% of patients achieving CR or VGPR after 16 infusions. Suppression of uninvolved FLC may result in delayed normalization of FLC ratio in some patients.
- Open Access
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 1901
The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy
Background: The International Society of Amyloidosis validated the criteria of hematologic response to therapy in AL amyloidosis, based on the reduction of free light chain (FLC) concentration and serum and urine immunofixation. Complete response (CR) predicted the longest survival and was defined by negative serum and urine immunofixation (s&u-IFE) with a normal FLC ratio (FLCR). Subsequently, we and others showed that, in patients with a difference between involved and uninvolved FLC (dFLC) between 20 and 49 mg/L, achieving a dFLC Methods: The prospectively maintained database of the Pavia Amyloidosis Center was searched for patients who were newly-diagnosed between 2004 and 2018 and who reached at least one the following endpoints 6 months after treatment initiation: 1) complete response (CR) or, in patients who do not qualify for CR, 2) normalization of involved-FLC concentration (normal-iFLC group), dFLC Results: A total of 434 patients (Table) were included, that were divided into the following groups: CR (161), normal-iFLCN (114), dFLC10 (144) and normal-FLCR (220). As expected, there was a partial overlap between the non-CR groups. No difference was seen between the CR and all the other groups in baseline variables: age, sex, organ involvement, Mayo 2004/European staging, and renal staging. Treatment was bortezomib-based in 261 subjects, melphalan/dexamethasone (MDex) in 128, IMiDs-based in 21, autologous stem cell transplant in 14, and therapy for IgM clones in the remaining 10 subjects. The reasons for not qualifying for CR in the normal-iFLC group was abnormal FLCR only in 4 (3%), positive s&u-IFE only in 81 (72%), and both in 29 (25%). The reason for not qualifying for CR in the dFLC10 group was abnormal FLCR only in 4 (3%), positive s&u-IFE only in 104 (72%) and both in 36 (25%). The median follow-up of living patients was 60 months. Patients who achieved CR enjoyed a significantly longer OS (58% alive at 10 years) compared to patients who reached any of the other endpoints but did not qualify for CR (Figure). Also median TNTD was significantly longer in patients who obtained CR (75 months) compared to the normal-iFLC group (33 months, PConclusion: Undetectable clonal disease by both negative serum and urine IFE and normal FLCR (CR) is associated with best survival in AL amyloidosis and should be the goal of therapy if tolerability and patient frailty allow. However, it is possible that novel immunotherapies, such as daratumumab, affect the concentration of uninvolved FLC, thus interfering with dFLC and FLCR, and this study should be validated in patients exposed to these agents. Approximately 40% of patients in CR relapse and eventually die. New sensitive tools to identify residual clonal disease (mass-spectrometry on serum and urine, next generation sequencing and next generation flow cytometry on bone marrow) are urgently needed to detect these patients and intervene before relapse.
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 1901
Open AccessThe Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy
Background: The International Society of Amyloidosis validated the criteria of hematologic response to therapy in AL amyloidosis, based on the reduction of free light chain (FLC) concentration and serum and urine immunofixation. Complete response (CR) predicted the longest survival and was defined by negative serum and urine immunofixation (s&u-IFE) with a normal FLC ratio (FLCR). Subsequently, we and others showed that, in patients with a difference between involved and uninvolved FLC (dFLC) between 20 and 49 mg/L, achieving a dFLC Methods: The prospectively maintained database of the Pavia Amyloidosis Center was searched for patients who were newly-diagnosed between 2004 and 2018 and who reached at least one the following endpoints 6 months after treatment initiation: 1) complete response (CR) or, in patients who do not qualify for CR, 2) normalization of involved-FLC concentration (normal-iFLC group), dFLC Results: A total of 434 patients (Table) were included, that were divided into the following groups: CR (161), normal-iFLCN (114), dFLC10 (144) and normal-FLCR (220). As expected, there was a partial overlap between the non-CR groups. No difference was seen between the CR and all the other groups in baseline variables: age, sex, organ involvement, Mayo 2004/European staging, and renal staging. Treatment was bortezomib-based in 261 subjects, melphalan/dexamethasone (MDex) in 128, IMiDs-based in 21, autologous stem cell transplant in 14, and therapy for IgM clones in the remaining 10 subjects. The reasons for not qualifying for CR in the normal-iFLC group was abnormal FLCR only in 4 (3%), positive s&u-IFE only in 81 (72%), and both in 29 (25%). The reason for not qualifying for CR in the dFLC10 group was abnormal FLCR only in 4 (3%), positive s&u-IFE only in 104 (72%) and both in 36 (25%). The median follow-up of living patients was 60 months. Patients who achieved CR enjoyed a significantly longer OS (58% alive at 10 years) compared to patients who reached any of the other endpoints but did not qualify for CR (Figure). Also median TNTD was significantly longer in patients who obtained CR (75 months) compared to the normal-iFLC group (33 months, PConclusion: Undetectable clonal disease by both negative serum and urine IFE and normal FLCR (CR) is associated with best survival in AL amyloidosis and should be the goal of therapy if tolerability and patient frailty allow. However, it is possible that novel immunotherapies, such as daratumumab, affect the concentration of uninvolved FLC, thus interfering with dFLC and FLCR, and this study should be validated in patients exposed to these agents. Approximately 40% of patients in CR relapse and eventually die. New sensitive tools to identify residual clonal disease (mass-spectrometry on serum and urine, next generation sequencing and next generation flow cytometry on bone marrow) are urgently needed to detect these patients and intervene before relapse.
- 1 September 2012
- Published by Elsevier in Clinical Nutrition Supplements
- Vol. 7 (1) , 161-162
PP060-MON MALNUTRITION AT DIAGNOSIS INDEPENDENTLY PREDICTS MORTALITY IN PATIENTS WITH SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS (AL)
- 1 September 2012
- Published by Elsevier in Clinical Nutrition Supplements
- Vol. 7 (1) , 161-162
PP060-MON MALNUTRITION AT DIAGNOSIS INDEPENDENTLY PREDICTS MORTALITY IN PATIENTS WITH SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS (AL)
- Open Access
- 31 January 2012
- Published by Wiley in American Journal of Hematology
- Vol. 87 (5) , 465-471
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure
In AL amyloidosis prognosis depends on the severity of heart dysfunction which is best assessed by natriuretic peptides (BNP and NT‐proBNP). However, their clearance relies on glomerular filtration rate (GFR) and their concentration increases with renal failure. We evaluated the diagnostic and prognostic performance of NT‐proBNP and BNP in 248 patients with AL amyloidosis with different degrees of renal failure. Patients were grouped according to GFR. Group 1 comprised 109 patients with GFR ≥60 mL/min/1.73 m2, Group 2, 77 subjects with GFR 2, and Group 3, 62 patients with GFR 2. The ability of natriuretic peptides to detect heart involvement and to predict survival in the three groups was assessed. Decreasing eGFR required higher cutoffs of both NT‐proBNP and BNP for detecting heart involvement and predicting survival. Both natriuretic peptides were independent prognostic markers in Groups 1 and 2, whereas in Group 3 only BNP independently predicted survival. Natriuretic peptides are powerful and useful markers of cardiac dysfunction and prognosis, provided that eGFR is considered in interpreting their clinical meaning. BNP should be preferred in patients with end‐stage renal failure. Am. J. Hematol. 87:465–471, 2012.
- 31 January 2012
- Published by Wiley in American Journal of Hematology
- Vol. 87 (5) , 465-471
Open AccessBest use of cardiac biomarkers in patients with AL amyloidosis and renal failure
In AL amyloidosis prognosis depends on the severity of heart dysfunction which is best assessed by natriuretic peptides (BNP and NT‐proBNP). However, their clearance relies on glomerular filtration rate (GFR) and their concentration increases with renal failure. We evaluated the diagnostic and prognostic performance of NT‐proBNP and BNP in 248 patients with AL amyloidosis with different degrees of renal failure. Patients were grouped according to GFR. Group 1 comprised 109 patients with GFR ≥60 mL/min/1.73 m2, Group 2, 77 subjects with GFR 2, and Group 3, 62 patients with GFR 2. The ability of natriuretic peptides to detect heart involvement and to predict survival in the three groups was assessed. Decreasing eGFR required higher cutoffs of both NT‐proBNP and BNP for detecting heart involvement and predicting survival. Both natriuretic peptides were independent prognostic markers in Groups 1 and 2, whereas in Group 3 only BNP independently predicted survival. Natriuretic peptides are powerful and useful markers of cardiac dysfunction and prognosis, provided that eGFR is considered in interpreting their clinical meaning. BNP should be preferred in patients with end‐stage renal failure. Am. J. Hematol. 87:465–471, 2012.
- 9 November 2011
- Published by Taylor & Francis in Amyloid
- Vol. 18 (4) , 216-221
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis
Background: Cardiac biomarkers play a major role in the identification of patients at risk of early death in AL amyloidosis, and a staging system based on amino-terminal pro-natriuretic peptide type-B (NT-proBNP) and troponins (cTn) is used for prognostic stratification. Adrenomedullin is produced by several tissues including the heart, and portends a poor prognosis in heart diseases. We investigated the ability of midregional proadrenomedullin (MR-proADM) to predict early death in AL amyloidosis. Methods: One-hundred and thirty consecutive patients with newly-diagnosed AL amyloidosis were prospectively enrolled. The impact on survival of NT-proBNP, cTnI and MR-proADM was evaluated. Results: The concentration of MR-proADM correlated with systolic and diastolic function, but did not reflect the amount of amyloid deposited in the heart. Moreover, MR-proADM was associated with non-cardiac markers of advanced disease. The staging system based on NT-proBNP and cTnI identified high-risk subjects, but could not discriminate good-risk and intermediate-risk patients. Conversely, a staging system based on MR-proADM and cTnI identified 3 groups with significantly different survivals. Conclusions: Midregional-proADM is a powerful prognostic marker in AL amyloidosis, which may not only reflect cardiac dysfunction but also widespread systemic disease, and can be combined with cTn for detecting patients at risk of early death.
- 9 November 2011
- Published by Taylor & Francis in Amyloid
- Vol. 18 (4) , 216-221
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis
Background: Cardiac biomarkers play a major role in the identification of patients at risk of early death in AL amyloidosis, and a staging system based on amino-terminal pro-natriuretic peptide type-B (NT-proBNP) and troponins (cTn) is used for prognostic stratification. Adrenomedullin is produced by several tissues including the heart, and portends a poor prognosis in heart diseases. We investigated the ability of midregional proadrenomedullin (MR-proADM) to predict early death in AL amyloidosis. Methods: One-hundred and thirty consecutive patients with newly-diagnosed AL amyloidosis were prospectively enrolled. The impact on survival of NT-proBNP, cTnI and MR-proADM was evaluated. Results: The concentration of MR-proADM correlated with systolic and diastolic function, but did not reflect the amount of amyloid deposited in the heart. Moreover, MR-proADM was associated with non-cardiac markers of advanced disease. The staging system based on NT-proBNP and cTnI identified high-risk subjects, but could not discriminate good-risk and intermediate-risk patients. Conversely, a staging system based on MR-proADM and cTnI identified 3 groups with significantly different survivals. Conclusions: Midregional-proADM is a powerful prognostic marker in AL amyloidosis, which may not only reflect cardiac dysfunction but also widespread systemic disease, and can be combined with cTn for detecting patients at risk of early death.